Cargando…

Comparative efficacy of switching to natalizumab in active multiple sclerosis

OBJECTIVE: To compare treatment efficacy and persistence in patients who switched to natalizumab versus those who switched between glatiramer acetate (GA) and interferon-beta (IFNβ) after an on-treatment relapse on IFNβ or GA using propensity score matched real-world datasets. METHODS: Patients incl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spelman, Timothy, Kalincik, Tomas, Zhang, Annie, Pellegrini, Fabio, Wiendl, Heinz, Kappos, Ludwig, Tsvetkova, Larisa, Belachew, Shibeshih, Hyde, Robert, Verheul, Freek, Grand-Maison, Francois, Izquierdo, Guillermo, Grammond, Pierre, Duquette, Pierre, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Oreja-Guevara, Celia, Hupperts, Raymond, Petersen, Thor, Barnett, Michael, Trojano, Maria, Butzkueven, Helmut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402083/ https://www.ncbi.nlm.nih.gov/pubmed/25909083 http://dx.doi.org/10.1002/acn3.180

Ejemplares similares

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Spelman, Timothy, et al.
Publicado: (2021)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

Predictors of disability worsening in clinically isolated syndrome
por: Jokubaitis, Vilija G, et al.
Publicado: (2015)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
por: Wiendl, Heinz, et al.
Publicado: (2016)

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
por: Trojano, Maria, et al.
Publicado: (2012)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS
por: Ribbons, Karen Ann, et al.
Publicado: (2015)

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry
por: Rojas, Juan Ignacio, et al.
Publicado: (2015)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome
por: Meyniel, Claire, et al.
Publicado: (2012)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

α4-integrin receptor desaturation and disease activity return after natalizumab cessation
por: Derfuss, Tobias, et al.
Publicado: (2017)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
por: Plavina, Tatiana, et al.
Publicado: (2014)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
por: Lefort, M., et al.
Publicado: (2022)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis
por: Kalincik, Tomas, et al.
Publicado: (2013)

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
por: Fernández, O., et al.
Publicado: (2012)

Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2008)

Treatment with natalizumab during the Covid-19 pandemic in multiple sclerosis patients
por: Díaz-Díaz, Judit, et al.
Publicado: (2021)

Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells
por: Spadaro, Michela, et al.
Publicado: (2015)

Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2010)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
por: González‐Suarez, Inés, et al.
Publicado: (2017)

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
por: Oreja-Guevara, Celia, et al.
Publicado: (2012)

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
por: Hillert, Jan, et al.
Publicado: (2021)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic
por: Díaz-Díaz, Judit, et al.
Publicado: (2021)

The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform
por: Jokubaitis, Vilija G., et al.
Publicado: (2013)

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
por: Chan, Andrew, et al.
Publicado: (2020)

Responsabilidad social empresaria : comunicación y cooperación en el área de la RSE /
por: Hupperts, Pierre
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_0t4d41rng63o3cng0rqv2k72u5